Michael Secora - 15 Aug 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
15 Aug 2024
Net transactions value
-$80,026
Form type
4
Filing time
19 Aug 2024, 19:09:22 UTC
Previous filing
15 Aug 2024
Next filing
12 Sep 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability $80,026 -11,962 -0.88% $6.69 1,353,381 15 Aug 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding RXRX Stock Option (Right to Buy) 573,885 15 Aug 2024 Class A Common Stock 0 $2.22 Direct F2
holding RXRX Stock Option (Right to Buy) 685,177 15 Aug 2024 Class A Common Stock 0 $2.22 Direct F3
holding RXRX Stock Option (Right to Buy) 3,914 15 Aug 2024 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 116,684 15 Aug 2024 Class A Common Stock 0 $11.40 Direct F4
holding RXRX Stock Option (Right to Buy) 404,857 15 Aug 2024 Class A Common Stock 0 $8.55 Direct F5
holding RXRX Stock Option (Right to Buy) 348,380 15 Aug 2024 Class A Common Stock 0 $10.09 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 The option, originally for 1,500,000 shares, vests incrementally upon satisfaction of certain liquidity events.
F3 The option, originally for 1,125,000 shares, vests as to one forty-eighth (1/48th) of the shares subject to the award one month after March 1, 2020, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter.
F4 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.